Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2016

Open Access 01-12-2016 | Research

Adipose tissue dysfunction increases fatty liver association with pre diabetes and newly diagnosed type 2 diabetes mellitus

Authors: Esteban Jorge-Galarza, Aida Medina-Urrutia, Rosalinda Posadas-Sánchez, Carlos Posadas-Romero, Guillermo Cardoso-Saldaña, Gilberto Vargas-Alarcón, Nacú Caracas-Portilla, Carmen González-Salazar, Margarita Torres-Tamayo, Juan Gabriel Juárez-Rojas

Published in: Diabetology & Metabolic Syndrome | Issue 1/2016

Login to get access

Abstract

Background

To evaluate the role of adipose tissue function on the association of fatty liver (FL) with impaired fasting glucose (IFG) or newly diagnosed type 2 diabetes mellitus (nT2D).

Methods

In 1264 subjects, computed tomography was used to evaluate FL and elevated visceral adipose tissue (VAT). Fasting plasma glucose, <5.6, 5.6–6.9 and ≥7 mmol/l, were used to defined normoglycemic (NG), IFG or nT2D, respectively. Elevated free fatty acids, low serum adiponectin levels and adipose tissue insulin resistance (Adipo-IR), were used as markers of adipose tissue dysfunction.

Results

Compared to NG subjects, those with IFG or nT2D had higher prevalence of FL and elevated VAT. FL was found to be independently associated with IFG and nT2D. Adipo-IR increased the association between FL and IFG [OR: 2.46 (95% I.C.: 1.73–3.49) to 5.42 (3.11–9.41)], whereas low adiponectin levels had a higher effect on the FL and nT2D association [OR: 4.26 (2.18–8.34) to 8.53 (2.96–24.55)].

Conclusion

Fatty liver was independently associated with IFG and nT2D. Our results indicate for the first time, that adipose tissue dysfunction increases these associations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959–71.CrossRefPubMed Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959–71.CrossRefPubMed
2.
go back to reference Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–77.CrossRefPubMedPubMedCentral Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–77.CrossRefPubMedPubMedCentral
3.
go back to reference Després J-P. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006;38(1):52–63.CrossRefPubMed Després J-P. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006;38(1):52–63.CrossRefPubMed
4.
go back to reference Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1389–97.CrossRefPubMed Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1389–97.CrossRefPubMed
5.
go back to reference Armstrong MJ, Hazlehurst JM, Hull D, Guo K, Borrows S, Yu J, et al. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab. 2014;16(7):651–60.CrossRefPubMedPubMedCentral Armstrong MJ, Hazlehurst JM, Hull D, Guo K, Borrows S, Yu J, et al. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab. 2014;16(7):651–60.CrossRefPubMedPubMedCentral
6.
go back to reference Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab. 2014;28(1):119–30.CrossRefPubMed Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab. 2014;28(1):119–30.CrossRefPubMed
7.
go back to reference Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103.CrossRefPubMedPubMedCentral Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103.CrossRefPubMedPubMedCentral
8.
go back to reference Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol. 2013;19(6):802–12.CrossRefPubMedPubMedCentral Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol. 2013;19(6):802–12.CrossRefPubMedPubMedCentral
9.
go back to reference Authors Task Force, Members Ryden L, Standl E, Bartnik M, Berghe GV, Betteridge J, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: the task force on diabetes and cardiovascular diseases of the european society of cardiology (ESC) and of the European association for the study of diabetes (EASD). Eur Heart J Suppl. 2007;9(Suppl C):C3–74.CrossRef Authors Task Force, Members Ryden L, Standl E, Bartnik M, Berghe GV, Betteridge J, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: the task force on diabetes and cardiovascular diseases of the european society of cardiology (ESC) and of the European association for the study of diabetes (EASD). Eur Heart J Suppl. 2007;9(Suppl C):C3–74.CrossRef
10.
go back to reference Smith JD, Borel A-L, Nazare J-A, Haffner SM, Balkau B, Ross R, et al. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study. J Clin Endocrinol Metab. 2012;97(5):1517–25.CrossRefPubMed Smith JD, Borel A-L, Nazare J-A, Haffner SM, Balkau B, Ross R, et al. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study. J Clin Endocrinol Metab. 2012;97(5):1517–25.CrossRefPubMed
11.
go back to reference Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150–9.CrossRefPubMedPubMedCentral Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150–9.CrossRefPubMedPubMedCentral
12.
go back to reference Hernández-Ono A, Monter-Carreola G, Zamora-González J, Cardoso-Saldaña G, Posadas-Sánchez R, Torres-Tamayo M, et al. Association of visceral fat with coronary risk factors in a population-based sample of postmenopausal women. Int J Obes Relat Metab Disord. 2002;26(1):33–9.CrossRefPubMed Hernández-Ono A, Monter-Carreola G, Zamora-González J, Cardoso-Saldaña G, Posadas-Sánchez R, Torres-Tamayo M, et al. Association of visceral fat with coronary risk factors in a population-based sample of postmenopausal women. Int J Obes Relat Metab Disord. 2002;26(1):33–9.CrossRefPubMed
13.
go back to reference Ginsberg HN, Zhang Y-L, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring). 2006;14(Suppl 1):41S–9S.CrossRefPubMed Ginsberg HN, Zhang Y-L, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring). 2006;14(Suppl 1):41S–9S.CrossRefPubMed
14.
go back to reference Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009;106(36):15430–5.CrossRefPubMedPubMedCentral Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009;106(36):15430–5.CrossRefPubMedPubMedCentral
15.
go back to reference Kantartzis K, Machann J, Schick F, Fritsche A, Häring H-U, Stefan N. The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia. 2010;53(5):882–9.CrossRefPubMed Kantartzis K, Machann J, Schick F, Fritsche A, Häring H-U, Stefan N. The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia. 2010;53(5):882–9.CrossRefPubMed
16.
go back to reference Villarreal-Molina T, Posadas-Romero C, Romero-Hidalgo S, Antúnez-Argüelles E, Bautista-Grande A, Vargas-Alarcón G, et al. The ABCA1 gene R230C variant is associated with decreased risk of premature coronary artery disease: the genetics of atherosclerotic disease (GEA) study. PLoS ONE. 2012;7(11):e49285.CrossRefPubMedPubMedCentral Villarreal-Molina T, Posadas-Romero C, Romero-Hidalgo S, Antúnez-Argüelles E, Bautista-Grande A, Vargas-Alarcón G, et al. The ABCA1 gene R230C variant is associated with decreased risk of premature coronary artery disease: the genetics of atherosclerotic disease (GEA) study. PLoS ONE. 2012;7(11):e49285.CrossRefPubMedPubMedCentral
17.
go back to reference Association AD. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2016;39(Supplement 1):S13–22.CrossRef Association AD. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2016;39(Supplement 1):S13–22.CrossRef
18.
go back to reference DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind BM. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol: the Lipid Research Clinics Prevalence Study. JAMA. 1986;256(17):2372–7.CrossRefPubMed DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind BM. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol: the Lipid Research Clinics Prevalence Study. JAMA. 1986;256(17):2372–7.CrossRefPubMed
19.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefPubMed Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefPubMed
20.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed
21.
go back to reference Maurovich-Horvat P, Massaro J, Fox CS, Moselewski F, O’Donnell CJ, Hoffmann U. Comparison of anthropometric, area- and volume-based assessment of abdominal subcutaneous and visceral adipose tissue volumes using multi-detector computed tomography. Int J Obes (Lond). 2007;31(3):500–6.CrossRef Maurovich-Horvat P, Massaro J, Fox CS, Moselewski F, O’Donnell CJ, Hoffmann U. Comparison of anthropometric, area- and volume-based assessment of abdominal subcutaneous and visceral adipose tissue volumes using multi-detector computed tomography. Int J Obes (Lond). 2007;31(3):500–6.CrossRef
22.
go back to reference McKimmie RL, Daniel KR, Carr JJ, Bowden DW, Freedman BI, Register TC, et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study. Am J Gastroenterol. 2008;103(12):3029–35.CrossRefPubMedPubMedCentral McKimmie RL, Daniel KR, Carr JJ, Bowden DW, Freedman BI, Register TC, et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study. Am J Gastroenterol. 2008;103(12):3029–35.CrossRefPubMedPubMedCentral
23.
go back to reference Balkau B, Lange C, Vol S, Fumeron F, Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol. 2010;10:56.CrossRefPubMedPubMedCentral Balkau B, Lange C, Vol S, Fumeron F, Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol. 2010;10:56.CrossRefPubMedPubMedCentral
24.
go back to reference Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35(4):873–8.CrossRefPubMedPubMedCentral Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35(4):873–8.CrossRefPubMedPubMedCentral
25.
go back to reference Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010;25(2):352–6.CrossRefPubMed Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010;25(2):352–6.CrossRefPubMed
26.
go back to reference Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-Kaluski D, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013;33(9):1406–12.CrossRefPubMed Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-Kaluski D, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013;33(9):1406–12.CrossRefPubMed
27.
go back to reference Ming J, Xu S, Gao B, Liu G, Ji Y, Yang F, Jia Y, Fang Y, Ji Q. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi’an, China: a five-year cohort study. Liver Int. 2015;35(11):2401–7.CrossRefPubMed Ming J, Xu S, Gao B, Liu G, Ji Y, Yang F, Jia Y, Fang Y, Ji Q. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi’an, China: a five-year cohort study. Liver Int. 2015;35(11):2401–7.CrossRefPubMed
28.
go back to reference Kelley DE, McKolanis TM, Hegazi RAF, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003;285(4):E906–16.CrossRefPubMed Kelley DE, McKolanis TM, Hegazi RAF, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003;285(4):E906–16.CrossRefPubMed
29.
go back to reference Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31(1):165–9.CrossRefPubMed Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31(1):165–9.CrossRefPubMed
30.
go back to reference Retnakaran R, Ye C, Hanley AJ, Harris SB, Zinman B. Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Obes Metab. 2012;14(1):91–3.CrossRefPubMed Retnakaran R, Ye C, Hanley AJ, Harris SB, Zinman B. Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Obes Metab. 2012;14(1):91–3.CrossRefPubMed
31.
go back to reference Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679–89.CrossRefPubMedPubMedCentral Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679–89.CrossRefPubMedPubMedCentral
32.
go back to reference Cheng S, Wiklund P, Autio R, Borra R, Ojanen X, Xu L, et al. Adipose tissue dysfunction and altered systemic amino acid metabolism are associated with non-alcoholic fatty liver disease. PLoS ONE. 2015;10(10):e0138889.CrossRefPubMedPubMedCentral Cheng S, Wiklund P, Autio R, Borra R, Ojanen X, Xu L, et al. Adipose tissue dysfunction and altered systemic amino acid metabolism are associated with non-alcoholic fatty liver disease. PLoS ONE. 2015;10(10):e0138889.CrossRefPubMedPubMedCentral
33.
go back to reference Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433–42.CrossRefPubMed Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433–42.CrossRefPubMed
34.
go back to reference Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metab, Clin Exp. 2011;60(3):313–26.CrossRef Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metab, Clin Exp. 2011;60(3):313–26.CrossRef
35.
go back to reference Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond). 2009;33(1):54–66.CrossRef Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond). 2009;33(1):54–66.CrossRef
36.
go back to reference Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci. 2002;967:363–78.CrossRefPubMed Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci. 2002;967:363–78.CrossRefPubMed
37.
go back to reference Brassard P, Frisch F, Lavoie F, Cyr D, Bourbonnais A, Cunnane SC, et al. Impaired plasma nonesterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. J Clin Endocrinol Metab. 2008;93(3):837–44.CrossRefPubMedPubMedCentral Brassard P, Frisch F, Lavoie F, Cyr D, Bourbonnais A, Cunnane SC, et al. Impaired plasma nonesterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. J Clin Endocrinol Metab. 2008;93(3):837–44.CrossRefPubMedPubMedCentral
38.
go back to reference Faerch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009;52(9):1714–23.CrossRefPubMed Faerch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009;52(9):1714–23.CrossRefPubMed
39.
go back to reference Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2004;230(1):276–80.CrossRefPubMed Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2004;230(1):276–80.CrossRefPubMed
Metadata
Title
Adipose tissue dysfunction increases fatty liver association with pre diabetes and newly diagnosed type 2 diabetes mellitus
Authors
Esteban Jorge-Galarza
Aida Medina-Urrutia
Rosalinda Posadas-Sánchez
Carlos Posadas-Romero
Guillermo Cardoso-Saldaña
Gilberto Vargas-Alarcón
Nacú Caracas-Portilla
Carmen González-Salazar
Margarita Torres-Tamayo
Juan Gabriel Juárez-Rojas
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2016
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-016-0189-6

Other articles of this Issue 1/2016

Diabetology & Metabolic Syndrome 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.